Storey, GB
Anthony Eamon Storey, Lincs GB
Patent application number | Description | Published |
---|---|---|
20100234611 | Fluorination Process of Anilide Derivatives and Benzothiazole Fluorinate Derivatives as in VIVO Imaging Agents - The invention relates to a process for preparation of a compound of formula (I): R | 09-16-2010 |
20110129419 | IN VIVO IMAGING AGENTS - The present invention relates to the field of medical imaging, and in particular to imaging of disease states associated with the upregulation of the chemokine receptor 5 (CCR5). Imaging agents, precursors and methods are provided which are useful in imaging such disease states. | 06-02-2011 |
20130129625 | IN VIVO IMAGING AGENTS - The present invention relates to the field of medical imaging, and in particular to imaging of disease states associated with the upregulation of the chemokine receptor 5 (CCR5). Imaging agents, precursors and methods are provided which are useful in imaging such disease states. | 05-23-2013 |
20130129626 | IN VIVO IMAGING AGENTS - The present invention relates to the field of medical imaging, and in particular to imaging of disease states associated with the upregulation of the chemokine receptor 5 (CCR5). Imaging agents, precursors and methods are provided which are useful in imaging such disease states. | 05-23-2013 |
20130225829 | FLUORINATION PROCESS - The invention relates to a process for preparation of a compound of formula (I): | 08-29-2013 |
20150328344 | Fluorination Process - The invention relates to a process for preparation of a compound of formula (I): | 11-19-2015 |
Anthony Eamon Storey, Buckinghamshire GB
Patent application number | Description | Published |
---|---|---|
20080279769 | Enzyme Inhibitor Imaging Agents - The present invention discloses that imaging agents which comprise a specific type of matrix metalloproteinase inhibitors (MMPi's) of the hydroxamate class labelled with an imaging moiety, are useful diagnostic imaging agents for in vivo imaging and diagnosis of the mammalian body. | 11-13-2008 |
David Graham Storey, Newcastle Upon Tyne GB
Patent application number | Description | Published |
---|---|---|
20100200624 | Harnesses - A harness for use with breathing apparatus has: a flexible hip plate | 08-12-2010 |
Dominic Storey, Hampshire GB
Patent application number | Description | Published |
---|---|---|
20120151497 | PROGRAMMATIC MODIFICATION OF A MESSAGE FLOW DURING RUNTIME - A message flow within a message broker can be identified. The message flow can include nodes and connections. The nodes can include a reflective node, a pre-defined node and a user-defined node. The message broker can be an intermediary computer program code able to translate a message from a first formal messaging protocol to a second formal messaging protocol. The code can be stored within a computer readable medium. The reflective node within the message flow can be selected. The reflective node can be associated with an external resource which can be an executable code. The external resource can be executed which can result in the modifying of the structure of the message flow. The modification can occur during runtime. The modification can include node and/or connection adding, altering, and deleting. | 06-14-2012 |
20120151498 | PROGRAMMATIC MODIFICATION OF A MESSAGE FLOW DURING RUNTIME - A message flow within a message broker can be identified. The message flow can include nodes and connections. The nodes can include a reflective node, a pre-defined node and a user-defined node. The message broker can be an intermediary computer program code able to translate a message from a first formal messaging protocol to a second formal messaging protocol. The code can be stored within a computer readable medium. The reflective node within the message flow can be selected. The reflective node can be associated with an external resource which can be an executable code. The external resource can be executed which can result in the modifying of the structure of the message flow. The modification can occur during runtime. The modification can include node and/or connection adding, altering, and deleting. | 06-14-2012 |
Dominic J. Storey, Eastleigh GB
Patent application number | Description | Published |
---|---|---|
20130031422 | DETECTING DEVICE IMPAIRMENT THROUGH STATISTICAL MONITORING - A tool for detecting potential impairment in an electronic device. The tool classifies the user input into various categories and determines some measurement, typically a rate of input per user or per time, for determining average use statistics of the electronic device. The tool then determines if a calculated measurement based on user inputs deviates from the average use statistics past some threshold level of deviation. In response to surpassing the threshold level of deviation, the tool identifies the electronic device as potentially impaired. | 01-31-2013 |
20130080452 | ACCESSING AND EDITING VIRTUALLY-INDEXED MESSAGE FLOWS USING STRUCTURED QUERY LANGAUGE (SQL) - At least one message flow file that stores a message flow is read by a processor. The message flow stored within the at least one message flow file is parsed. The message flow is organized within a memory as a message flow database structure. Entries within the message flow database structure represent nodes, connections, and properties used by the message flow. The message flow database structure is edited in response to receipt of a structured query language (SQL) statement that specifies a change to the message flow database structure. | 03-28-2013 |
20160048257 | USER INTERFACE TAP SELECTION ON TOUCHSCREEN DEVICE - A tap associated with an active area on a user interface of a touchscreen device is received at a first time. The active area is associated with an origination time. It is determined that a period of time between the origination time and the first time is within a specified period of time. In response to the determining, an action associated with the active area is not performed. | 02-18-2016 |
Garry Storey, Flintshire GB
Patent application number | Description | Published |
---|---|---|
20150354096 | PROCESSING OF CHEMICALLY MODIFIED CELLULOSIC FIBRES - A chemically modified cellulosic fibre or filament having a moisture content of at least 7% by weight obtained by a process comprising the steps of (i) obtaining cellulosic fibres or filament and chemically modifying the cellulose by substitution to increase its absorbency; (ii) washing the fibres after step (i) in a mixture comprising water and up to 99% by weight of water-miscible organic solvent; (iii) drying the fibres to a moisture content of at least 7% by weight, tart abstract here | 12-10-2015 |
Gregor Storey, Oxford GB
Patent application number | Description | Published |
---|---|---|
20120057245 | VALVE DEVICE FOR A VARIABLE FOCUS LENS - A valve device for a variable lens comprises: an inlet for receiving fluid from a reservoir; an outlet for passing fluid to a lens cavity; and a valve member, the valve member comprising a passageway for fluid communication between the inlet and outlet and a valve for closing the passageway; wherein the valve is actuated by turning the valve member about an axis of rotation and the passageway extends along the valve member in the axial direction. | 03-08-2012 |
20130141692 | EYEGLASSES AND MEANS FOR THEIR ADJUSTMENT - Eyeglasses which comprise a pair of optical plates for each eye. Each of the optical plates is made up of a front plate and a rear plate and a return and hinge mechanism links the optical plates of each pair with one another. An adjustment mechanism facilitates relative movement of the optical plates, of each pair, in a plane substantially perpendicular to a viewing direction of the eyeglasses. The return and hinge mechanism and the adjustment mechanism are decoupled. | 06-06-2013 |
20140211148 | ADJUSTABLE REFRACTIVE OPTICAL DEVICE - A method of making a lens having adjustable optical power is disclosed. The lens is adjustable by relative lateral translation of at least two lens elements. The method may comprise providing a function yielding optical properties of the lens from starting geometries for the lens elements; refining the function to approximate required gaze angle optical performance over a range of said lateral translation; and using the refined function to derive geometries for making the lens elements. The function may comprise first and second functional parts respectively for the lens elements, and the method comprises using the function to derive geometries for making the lens elements, wherein the function relates optical path difference to a position across the lens elements, and the rate of change of curvature of the first functional part with position is different to the rate of change of curvature of the second functional part with position. There is also disclosed a lens having adjustable optical power. The lens is adjustable by relative lateral translation of at least two lens elements. The adjustable lens may be used for corrective eyeglasses. | 07-31-2014 |
Gregor Allan Storey, Oxfordshire GB
Patent application number | Description | Published |
---|---|---|
20140253873 | METHOD OF FORMING VARIABLE FOCUS EYEWEAR - A method of forming a support member to a flexible membrane is provided by the present disclosure. In one form, the method includes placing the flexible membrane onto an outer periphery of a fixed tool, translating a movable tool towards the fixed tool, and engaging the flexible membrane such that the flexible membrane is deformed and placed into tension. A molten resin is then injected into a support ring molding cavity, and the resin is allowed to cool such that the support ring is secured to the tensioned flexible membrane. The movable tool is then translated away from the fixed tool to eject a flexible membrane and support ring assembly. | 09-11-2014 |
20150331257 | METHOD OF FORMING VARIABLE FOCUS EYEWEAR - A method of forming a support member to a flexible membrane is provided by the present disclosure. In one form, the method includes placing the flexible membrane onto an outer periphery of a fixed tool, translating a movable tool towards the fixed tool, and engaging the flexible membrane such that the flexible membrane is deformed and placed into tension. A molten resin is then injected into a support ring molding cavity, and the resin is allowed to cool such that the support ring is secured to the tensioned flexible membrane. The movable tool is then translated away from the fixed tool to eject a flexible membrane and support ring assembly. | 11-19-2015 |
Gregor Allan Storey, Oxford GB
Patent application number | Description | Published |
---|---|---|
20130141690 | REFRACTIVE EYEWEAR - An optical apparatus ( | 06-06-2013 |
Helen Storey, London GB
Patent application number | Description | Published |
---|---|---|
20100213129 | APPARATUS AND METHOD FOR PURIFYING WATER BY FORWARD OSMOSIS - A water purification apparatus comprising a semi-permeable membrane capable of being contacted with a water source; a superabsorbent polymer capable of absorbing water across said semi-permeable membrane; a pressure application surface capable of transmitting pressure to the gel; and a permeable membrane through which absorbed water is capable of being released from the gel upon application of pressure thereto from said pressure application surface, wherein said permeable membrane is isolated in use from the water source by an isolation means | 08-26-2010 |
John Storey, Strathcarron Ross-Shire GB
Patent application number | Description | Published |
---|---|---|
20160129009 | HIGH PURITY DIAMINOPHENOTHIAZINIUM COMPOUNDS INCLUDING METHYLTHIONINIUM CHLORIDE (MTC) - This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7 diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiaziniumcompounds”) including Methythioninium Chloride (MTC) (also known as Methylene Blue). In one embodiment, the method comprises the steps of, in order: nitrosylation (NOS); nitrosyl reduction (NR); thiosulfonic acid formation (TSAF); oxidative coupling (OC); Cr(VI) reduction (CR); isolation and purification of zwitterionic intermediate (IAPOZI); ring closure (RC); chloride salt-formation (CSF); one of: sulphide treatment (ST); dimethyldithiocarbamate treatment (DT); carbonate treatment (CT); ethylenediaminetetraacetic acid treatment (EDTAT); organic extraction (OE); and recrystallisation (RX). The present invention also pertains to the resulting (high purity) compounds, compositions comprising them (e.g., tablets, capsules), and their use in methods of inactivating pathogens, and methods of medical treatment and diagnosis, etc., for example, for tauopathies, Alzheimer's disease (AD), skin cancer, melanoma, viral diseases, bacterial diseases, or protozoal diseases. | 05-12-2016 |
John Storey, Cheshire GB
Patent application number | Description | Published |
---|---|---|
20100141662 | COMMUNICATION NETWORK AND DEVICES FOR TEXT TO SPEECH AND TEXT TO FACIAL ANIMATION CONVERSION - A communication system comprises a sending device, a receiving device and a network which connects the sending device to the receiving device. The sending device comprises at least one user operable input for entering a sequence of textual characters. as a message and transmission means for sending the message across the network. The receiving device comprises a memory which stores a plurality of head images, each one being associated with a different sending device and comprising an image of a head viewed from the front, receiver means for receiving the message comprising the sequence of textual characters, text to speech converting means for converting the text characters of the message into an audio message corresponding to the sequence of text characters and animating means for generating an animated partial 3D image of a head from the head image stored in the memory which is associated with the sender of the message. The animating means animates at least one facial feature of the head, the animation corresponding the movements made by the head when reading the message. A display displays the animated partial 3D head; and a loudspeaker outputs the audio message in synchronisation with the displayed head. | 06-10-2010 |
John James Storey, Wollaton Nottingham GB
Patent application number | Description | Published |
---|---|---|
20100202725 | LASER ILLUMINATION DEVICE - An Electrically Switchable Bragg Grating (ESBG) despeckler device comprising at least one ESBG element recorded in a hPDLC sandwiched between transparent substrates to which transparent conductive coatings have been applied. At least one of said coatings is patterned to provide a two-dimensional array of independently switchable ESBG pixels. Each ESBG pixel has a first unique speckle state under said first applied voltage and a second unique speckle state under said second applied voltage. | 08-12-2010 |
20120281943 | LASER ILLUMINATION DEVICE - An Electrically Switchable Bragg Grating (ESBG) despeckler device comprising at least one ESBG element recorded in a hPDLC sandwiched between transparent substrates to which transparent conductive coatings have been applied. At least one of said coatings is patterned to provide a two-dimensional array of independently switchable ESBG pixels. Each ESBG pixel has a first unique speckle state under said first applied voltage and a second unique speckle state under said second applied voltage. | 11-08-2012 |
John James Storey, Wallaton Nottingham GB
Patent application number | Description | Published |
---|---|---|
20140037242 | LASER ILLUMINATION DEVICE - An Electrically Switchable Bragg Grating (ESBG) despeckler device comprising at least one ESBG element recorded in a hPDLC sandwiched between transparent substrates to which transparent conductive coatings have been applied. At least one of said coatings is patterned to provide a two-dimensional array of independently switchable ESBG pixels. Each ESBG pixel has a first unique speckle state under said first applied voltage and a second unique speckle state under said second applied voltage. | 02-06-2014 |
20160124241 | LASER ILLUMINATION DEVICE - An Electrically Switchable Bragg Grating (ESBG) despeckler device comprising at least one ESBG element recorded in a hPDLC sandwiched between transparent substrates to which transparent conductive coatings have been applied. At least one of said coatings is patterned to provide a two-dimensional array of independently switchable ESBG pixels. Each ESBG pixel has a first unique speckle state under said first applied voltage and a second unique speckle state under said second applied voltage. | 05-05-2016 |
John Mervyn David Storey, Strathcarron Ross-Shire GB
Patent application number | Description | Published |
---|---|---|
20080207603 | Methods of Chemical Synthesis and Purification of Diaminophenothiazinium Compounds Including Methylthioninium Chloride (Mtc) - This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7 diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiazinium compounds”) including Methylthioninium Chloride (MTC) (also known as Methylene Blue). In one embodiment, the method comprises the steps of, in order: nitrosylation (NOS); nitrosyl reduction (NR); thiosulfonic acid formation (TSAF); oxidative coupling (OC); Cr(VI) reduction (CR); isolation and purification of zwitterionic intermediate (IAPOZI); ring closure (RC); chloride salt formation (CSF); one of: sulphide treatment (ST); dimethyldithiocarbamate treatment (DT); carbonate treatment (CT); ethylenediaminetetraacetic acid treatment (EDTAT); organic extraction (OE); and recrystallisation (RX). The present invention also pertains to the resulting (high purity) compounds, compositions comprising them (e.g., tablets, capsules), and their use in methods of inactivating pathogens, and methods of medical treatment and diagnosis, etc., for example, for tauopathies, Alzheimer's disease (AD), skin cancer, melanoma, viral diseases, bacterial diseases, or protozoal diseases. Wherein: each of R | 08-28-2008 |
20110021510 | METHODS OF CHEMICAL SYNTHESIS AND PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INCLUDING METHYLTHIONINIUM CHLORIDE (MTC) - This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7 diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiaziniumcompounds”) including Methylhioninium Chloride (MTC) (also known as Methylene Blue). In one embodiment, the method comprises the steps of, in order: nitrosylation (NOS); nitrosyl reduction (NR); thiosulfonic acid formation (TSAF); oxidative coupling (OC); Cr(VI) reduction (CR); isolation and purification of zwitterionic intermediate (IAPOZI); ring closure (RC); chloride salt-formation (CSF); one of: sulphide treatment (ST); dimethyldithiocarbamate treatment (DT); carbonate treatment (CT); ethylenediaminetetraacetic acid treatment (EDTAT); organic extraction (OE); and recrystallisation (RX). The present invention also pertains to the resulting (high purity) compounds, compositions comprising them (e.g., tablets, capsules), and their use in methods of inactivating pathogens, and methods of medical treatment and diagnosis, etc., for example, for tauopathies, Alzheimer's disease (AD), skin cancer, melanoma, viral diseases, bacterial diseases, or protozoal diseases. | 01-27-2011 |
John Mervyn David Storey, Old Aberdeen GB
Patent application number | Description | Published |
---|---|---|
20100290986 | THERAPEUTIC USE OF DIAMINOPHENOTHIAZINES - The present invention relates generally to methods and materials for use in the treatment or prophylaxis of diseases, for example cognitive disorders, using diaminophenothiazines. In particular it relates to treatments having optimised pharmacokinetic properties, and dosage forms are intended to improve the relative cognitive or CNS benefits of the diaminophenothiazines, for instance compared to haematological effects. | 11-18-2010 |
20110118242 | 3,7-DIAMINO-10H-PHINOTHIAZINE SALTS AND THEIR USE - This invention pertains generally to the field of phenothiazine compounds, and more particularly to certain stably reduced phenothiazine compounds, specifically, certain 3,7-diamino-10H-phenothiazine (DAPTZ) compounds of the following formula: | 05-19-2011 |
20110245504 | SYNTHESIS OF 9-(ARYLALKYL)-1,2,3,4-TETRAHYDRO-y-CARBOLINE AND ANALOGUES AND INTERMEDIATES - The present invention pertains generally to methods of preparing certain 9-(arylalkyl)-1,2,3,4-tetrahydro-γ-carboline compounds and their analogues, and especially to methods of preparing dimebon. The present invention also pertains to methods of preparing certain intermediate compounds which find use in the synthesis of the 9-(arylalkyl)-1,2,3,4-tetrahydro-γ-carboline compounds. | 10-06-2011 |
20110294795 | METHODS OF SYNTHESIS AND/OR PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS - Described are compositions and methods of making high purity diaminophenothiazinium compounds of the following formula | 12-01-2011 |
20110300074 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS - This invention pertains generally to processes, uses, methods and materials utilising particular xanthylium compounds, including compounds of formula (I) and (II), as further defined herein. These compounds are useful as drugs, for example, in the treatment of tauopathies, such as Alzheimer's disease. | 12-08-2011 |
20120058995 | METHODS OF CHEMICAL SYNTHESIS OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INVOLVING THE USE OF PERSULFATE OXIDANTS - This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7-diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiazinium compounds”) including Methylthioninium Chloride (MTC) (also known as Methylene Blue). In one embodiment, the e//i method comprises the steps of in order: a thiosulfonic acid formation (TSAF) as illustrated below, wherein the reaction is carried out in the presence of a thio sulfate and an oxidizing agent that is or comprises persulfate an oxidative coupling (OC); and a ring closure (RC). The resulting compounds and compositions comprising them (e.g., tablets, capsules) are useful in methods of medical treatment and diagnosis, etc., for example, tauopathies, or Alzheimer's disease (AD). | 03-08-2012 |
20130315992 | PHENOTHIAZINE DIAMINIUM SALTS AND THEIR USE - The invention relates to compounds of general formula (I): wherein: each of R | 11-28-2013 |
20130317012 | METHODS OF SYNTHESIS AND/OR PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS - Described are methods of synthesis and/or purification of certain 3,7-diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiazinium compounds”) including Methylthioninium Chloride (MTC) (also known as Methylene Blue), the resulting (high purity) compounds, compositions comprising such compounds (e.g., tablets, capsules), and the use of such high purity compounds. The compounds are useful in inactivating pathogens, and methods of medical treatment, prophylaxis, and diagnosis of diseases including a tauopathy, related neurological and infectious diseases. | 11-28-2013 |
20140161731 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS - Described are a compound of formula (II) or (III): | 06-12-2014 |
20140221359 | 3,7-DIAMINO-10H-PHENOTHIAZINE SALTS AND THEIR USE - Described are methods of prepraing reduced 3,7-diamino-10H-phenothiazine (DAPTZ) compounds of formula: | 08-07-2014 |
20160030444 | THERAPEUTIC USE OF DIAMINOPHENOTHIAZINES - Described are methods and materials for use in the treatment or prophylaxis of diseases, for example cognitive disorders, using diaminophenothiazines. In particular it relates to treatments having optimised pharmacokinetic properties, and dosage forms are intended to improve the relative cognitive or CNS benefits of the diaminophenothiazines, for instance compared to haematological effects. | 02-04-2016 |
20160051559 | 3, 7-DIAMINO-10H-PHENOTHIAZINE SALTS AND THEIR USE - Described are methods of preparing reduced 3,7-diamino-10H-phenothiazine (DAPTZ) compounds of formula: | 02-25-2016 |
John Mervyn David Storey, Aberdeenshire GB
Patent application number | Description | Published |
---|---|---|
20090054419 | 3,7-DIAMINO-10H-PHENOTHIAZINE SALTS AND THEIR USE - This invention pertains generally to the field of phenothiazine compounds, and more particularly to certain stably reduced phenothiazine compounds, specifically, certain 3,7 diamino-10H-phenothiazine (DAPTZ) compounds of the following formula wherein: each of R | 02-26-2009 |
20090259040 | METHODS OF SYNTHESIS AND/OR PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS - This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesis and/or purification of certain 3,7 diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiazinium compounds”) including Methylthioninium Chloride (MTC) (also known as Methylene Blue). The present invention also pertains to the resulting (high purity) compounds, compositions comprising them (e.g., tablets, capsules), and their use in methods of inactivating pathogens, and methods of medical treatment, prophylaxis, and diagnosis, etc., for example, a tauopathy; a disease of tau protein aggregation; Alzheimer's disease (AD); Pick's disease; Progressive Supranuclear Palsy (PSP); fronto temporal dementia (FTD); parkinsonism linked to chromosome 17 (FTDP-17); disinhibition-dementia-parkinsonism-amyotrophy complex (DDPAC); pallido-ponto-nigral degeneration (PPND); Guam-ALS syndrome; pallido-nigro-luysian degeneration (PNLD); cortico-basal degeneration (CBD); mild cognitive impairment (MCI); skin cancer; melanoma; methemoglobinemia; a viral infection; a bacterial infection; a protozoal infection; a parasitic infection; malaria; visceral leishmaniasis; African sleeping sickness; toxoplasmosis; giardiasis; Chagas' disease; Hepatitis C virus (HCV) infection; human immunodeficiency virus (HIV) infection; West Nile virus (WNV) infection; a synucleinopathy; Parkinson's disease (PD); dementia with Lewy bodies (DLB); multiple system atrophy (MSA); drug-induced parkinsonism; and pure autonomic failure (PAF). | 10-15-2009 |
Lynda Jane Storey, Scotland GB
Patent application number | Description | Published |
---|---|---|
20110171739 | LIGANDS FOR AGGREGATED TAU MOLECULES - Provided are certain benzothiazole, imidazothiazole, imidazopyrimidine and imidazopyridine compounds, including, for example: formula (I) and pharmaceutically and physiologically acceptable salts, hydrates, and solvates thereof. Such compounds can be used as diagnostic ligands or labels of tau protein and PHF. | 07-14-2011 |
Piers Christian Storey, Church Brow GB
Patent application number | Description | Published |
---|---|---|
20150196074 | Body Protection - A body protection assembly is disclosed for protecting a human body from injury due to an impact. An internal planar structure ( | 07-16-2015 |
Richard Storey, Cheshire GB
Patent application number | Description | Published |
---|---|---|
20110152297 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS - The invention concerns quinazoline derivatives of the Formula I, or pharmaceutically acceptable salts thereof: | 06-23-2011 |
Richard Anthony Storey, Macclesfield GB
Patent application number | Description | Published |
---|---|---|
20090030058 | TOSYLATE SALT OF 6- (4-BR0M0-2-CHL0R0PHENYLAMIN0) -7-FLUORO-N- (2-HYDROXYETHOXY) -3-METHYL-3H-BENZIMI DAZOLE- 5 - CARBOXAMIDE , MEK INHIBITOR USEFUL IN THE TREATMENT OF CANCER - The present invention relates to a tosylate salt of Compound 1 and polymorphs thereof, in particular crystalline and amorphous forms of Compound 1 tosylate salt, and methods of preparation thereof. Pharmaceutical compositions containing these salts as active ingredient, their use in the manufacture of medicaments for use in the treatment and/or prophylaxis of proliferative disease states, such as cancer, in the human or animal body, and their use in methods for the treatment and/or prophylaxis of proliferative disease states, such as cancer, in the human or animal body are also described. | 01-29-2009 |
20120253049 | NOVEL HYDROGEN SULFATE SALT - The present invention relates to Compound 1 hydrogen sulfate salt and solvates, crystalline forms and amorphous forms thereof, and to processes for their preparation. | 10-04-2012 |
Richard Anthony Storey, Cheshire GB
Patent application number | Description | Published |
---|---|---|
20080280957 | Heterocyclic Inhibitors of Mek and Methods of Use Thereof - Disclosed are MEK inhibitors useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds. | 11-13-2008 |
20080312261 | 4- (4-Bromo-2-Fluoroanilino) -6- Methoxy-7- (1-Methylpiperidin-4-Ylmethoxy) Quinazoline Monohydrate - The present invention relates to a ZD6474 monohydrate, to processes for the preparation of a ZD6474 monohydrate, to pharmaceutical compositions comprising a ZD6474 monohydrate as the active ingredient, to the use of a ZD6474 monohydrate in the manufacture of medicaments for use in the production of antiangiogenic and/or vascular permeability reducing effects in warm-blooded animals such as humans, and to the use of a ZD6474 monohydrate in methods for the treatment of disease states associated with angiogenesis and/or increased vascular permeability, such as cancer, in warm-blooded animals such as humans. | 12-18-2008 |
20100016393 | NOVEL HYDROGEN SULFATE SALT - The present invention relates to Compound 1 hydrogen sulfate salt and solvates, crystalline forms and amorphous forms thereof, and to processes for their preparation. Compound I | 01-21-2010 |